e-learning
resources
Amsterdam 2011
Monday, 26.09.2011
Pulmonary hypertension in hypoxic lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Experience with pulmonary selective vasodilator treatment in COPD with severe pulmonary hypertension
S. Ulrich, G. Suna, L. Huber, U. Treder, R. Speich (Zurich, Switzerland)
Source:
Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease
Session:
Pulmonary hypertension in hypoxic lung disease
Session type:
Thematic Poster Session
Number:
2367
Disease area:
Airway diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Ulrich, G. Suna, L. Huber, U. Treder, R. Speich (Zurich, Switzerland). Experience with pulmonary selective vasodilator treatment in COPD with severe pulmonary hypertension. Eur Respir J 2011; 38: Suppl. 55, 2367
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
The definition of pulmonary hypertension: history, practical implications and current controversies
Related content which might interest you:
Acute pulmonary vasoreactivity to beraprost in patients with severe pulmonary hypertension
Source: Eur Respir J 2002; 20: Suppl. 38, 597s
Year: 2002
Treatment of pulmonary hypertension in chronic obstructive pulmonary disease
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313
Year: 2006
Oral sildenafil is a potent pulmonary vasodilator and improves gas exchange in patients with COPD with pulmonary hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 426s
Year: 2006
Pulmonary hypertension in COPD
Source: Eur Respir J 2008; 32: 1371-1385
Year: 2008
Effects of Valsartan on pulmonary hemodynamics in patients with chronic obstructive pulmonary disease (COPD) and secondary pulmonary hypertension
Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies
Year: 2019
Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children
Source: Eur Respir J 2011; 37: 70-77
Year: 2011
Medical treatment in persistent pulmonary hypertension after pulmonary thrombendarterectomy in patients with chronic thrombembolic pulmonary hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 364s
Year: 2006
Acute vasodilator response in different forms of pre-capillary pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013
Long-term treatment of pulmonary hypertension with aerosolized iloprost
Source: Eur Respir J 2001; 17: 8-13
Year: 2001
Treatment with sildenafil for pulmonary hypertension in pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 562s
Year: 2005
Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Effects of bosentan in patients with severe pulmonary hypertension and mild-to-moderate COPD
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009
Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018
The effect of short-acting beta-two-agonist on pulmonary rehabilitation in chronic obstructive pulmonary disease
Source: Annual Congress 2009 - Pulmonary rehabilitation: extending the scope and benefit of rehabilitation for patients with chronic respiratory disease
Year: 2009
Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension
Source: Eur Respir Rev 2009; 19: 64-67
Year: 2010
Vasodilator treatment in chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2003 - Update on chronic thromboembolic pulmonary hypertension
Year: 2003
The effectiveness of pulmonary rehabilitation in Russian patients with COPD complicated by pulmonary artery hypertension
Source: Annual Congress 2009 - Pulmonary rehabilitation: extending the scope and benefit of rehabilitation for patients with chronic respiratory disease
Year: 2009
Bosentan and pulmonary hypertension in patients affected by chronic obstructive pulmonary disease
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept